Author(s):
Ganesh Narayan Sharma, Ch. Praveen Kumar, Birendra Shrivastava, B. Kumar
Email(s):
praveenchembeti@gmail.com
DOI:
10.52711/0974-360X.2021.00652 
Address:
Ganesh Narayan Sharma1, Ch. Praveen Kumar1, Birendra Shrivastava1, B. Kumar2
1School of Pharmaceutical Sciences, Jaipur National University, Jaipur - 307017, India.
2Ratnam Institute of Pharmacy, Pidathapolur (V), SPSR Nellore, Andhra Pradesh, Dt. 524346, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 7,
Year - 2021
ABSTRACT:
Nanomaterials can be used as drug carriers with multiple features, including target delivery triggered by environmental, pH, thermal responses, enhanced biocompatibility, and the ability to cross the blood-brain barrier. Chitosan (CS) is a natural polysaccharide largely obtained from marine crustaceans. It provides drug delivery vector for therapeutic CS and diagnostic CS, owing to its biocompatibility, biodegradability, low toxicity, and structural variability. Derivatives of CS such as quaternized CS, thiolated CS and carboxylated CS have enhanced its effectiveness in oral absorption of macromolecular drugs. This review discusses different forms of nanomaterials generated from CS and its derivatives for controlled drug delivery.
Cite this article:
Ganesh Narayan Sharma, Ch. Praveen Kumar, Birendra Shrivastava, B. Kumar. Advances in Oral Chitosan Based Nano Delivery System for colon Targeted Drug Delivery in Inflammatory Bowel Disease. Research Journal of Pharmacy and Technology. 2021; 14(7):3769-4. doi: 10.52711/0974-360X.2021.00652
Cite(Electronic):
Ganesh Narayan Sharma, Ch. Praveen Kumar, Birendra Shrivastava, B. Kumar. Advances in Oral Chitosan Based Nano Delivery System for colon Targeted Drug Delivery in Inflammatory Bowel Disease. Research Journal of Pharmacy and Technology. 2021; 14(7):3769-4. doi: 10.52711/0974-360X.2021.00652 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-7-49
REFERENCES:
1. Fix JA. Oral controlled release technology for peptides: status and future prospects. Pharm. Res. 1996; 13, 1760–1764.
2. Thanou M, J. Verhoef, Junginger H. Oral drug absorption enhancement by Chitosan and its derivatives. Adv. Drug Deliv. Rev. 52, 2001, 117–126.
3. Chen MC, Mi FL, Liao ZX, Sung HW. Chitosan: its applications in drug-eluting devices, Adv. Polym. Sci. 243, 2011, 185–230.
4. Rinaudo M. Chitin and Chitosan: properties and applications. Prog. Polym. Sci. 31,2006, 603–632.
5. Y. Maezaki, K. Tsuji, Y. Nakagawa, Y. Kawai, M. Akimoto, T. Tsugita, W. Takekawa, A. Terada, H. Hara, T. Mitsuoka, Hypocholesterolemic effect of Chitosan in adult males, Biosci. Biotechnol. Biochem. 57, 1993, 1439–1444.
6. Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue. Nanomedicine: Nanotechnology, Biology, and Medicine 11, 2015, 1117–1132.
7. Zhanga S, Langera R, Traversoa G. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. Nano Today 16, 2017, 82–96.
8. Arai K, Kinumari T, Fujita T. On the toxicity of Chitosan. Bull. Tokai Reg. Fish. Res. Lab. 56, 1986, 889–892.
9. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with Chitosan –DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5, 1999, 387–391.
10. Sakloetsakun D, Perera G, Hombach J, Millotti G, Bernkop-Schnürch A. The impact of vehicles on the mucoadhesive properties of orally administrated nanoparticles: a case study with Chitosan -4-thiobutylamidine conjugate, AAPS PharmSciTech 11,2010,1185–1192.
11. Sonia T, Sharma C. Chitosan and its derivatives for drug delivery perspective, Adv. Polym. Sci. 243, 2011, 23–54.
12. Sonaje K, Lin KJ, Tseng MT, Wey SP, Su FY, Chuang EY, Hsu CW, Chen CT, Sung HW. Effects of Chitosan -nanoparticle-mediated tight junction opening on the oral absorption of endotoxins, Biomaterials 32 ,2011, 8712–8721.
13. Y.H. Lin, C.T. Chen, H.F. Liang, A.R. Kulkarni, P.W. Lee, C.H. Chen, H.W. Sung, Novel nanoparticles for oral insulin delivery via the paracellular pathway, Nanotechnology 18,2007, 1051-02.
14. H.N. Nguyen, S.P. Wey, J.H. Juang, K. Sonaje, Y.C. Ho, E.Y. Chuang, C.W. Hsu, T.C. Yen, K.J. Lin, H.W. Sung, The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo, Biomaterials 32 ,2011, 2673–2682.
15. A.F. Kotze, H.L. Luessen, A.G. de Boer, J.C. Verhoef, H.E. Junginger, Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments, Eur. J. Pharm. Sci. 7, 1999, 145–151.
16. A. Singla, M. Chawla, Chitosan: some pharmaceutical and biological aspects—an update, J. Pharm. Pharmacol. 53,2001, 1047–1067.
17. R. Hejazi, M. Amiji, CS-based gastrointestinal delivery systems, J. Control. Release 89, 2003, 151–165.
18. A. Bernkop-Schnürch, M. Hornof, T. Zoidl, Thiolated polymers—thiomers: synthesis and in vitro evaluation of Chitosan–2-iminothiolane conjugates, Int. J. Pharm. 260, 2003, 229–237.
19. M. Roldo, M. Hornof, P. Caliceti, A. Bernkop-Schnürch, Mucoadhesive thiolated Chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation, Eur. J. Pharm. Biopharm. 57, 2004, 115–121.
20. A. Bernkop-Schnürch, D. Guggi, Y. Pinter, Thiolated Chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system, J. Control. Release 94,2004,177–186.
21. S.P. Balcerzak, W.C. Lane, J.W. Bullard, Surface structure of intestinal epithelium, Gastroenterology 58, 1970, 49–55.
22. N. Angelova, D. Hunkeler, Effect of preparation conditions on properties and permeability of CSsodium hexametaphosphate capsules, J. Biomater. Sci. Polym. Ed. 12,2001, 1317–1337.
23. I. Kadiyala, Y. Loo, K. Roy, J. Rice, K.W. Leong, Transport of Chitosan –DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes, Eur. J. Pharm. Sci. 39, 2010, 103–109.
24. A.T. Florence, Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov. Today 2, 2005, 75–81.